Results of the phase I clinical trial of the investigational agent DMOT4039A has found the drug to be well tolerated in some patients and display initial evidence of anti-cancer activity among patients suffering from pancreatic and ovarian cancers, researchers told the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate ...
Read MoreYou have just read an article categorized health
titled Results Show Experimental Drug to be Effective in Some Patients With Pancreatic or Ovarian Cancer.
Written by:
editor - Saturday, May 31, 2014
There are currently no comments for "Results Show Experimental Drug to be Effective in Some Patients With Pancreatic or Ovarian Cancer"
Post a Comment